文献速递心脑血管急症消化、代谢与肾脏急症

降钙素基因相关肽单克隆抗体与偏头痛退伍军人SARS-CoV-2感染及重症COVID-19结局风险

Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论回顾性队列显示,启动CGRP单抗与SARS-CoV-2检测阳性及重症COVID-19结局无显著关联,作者认为疫情期间可用于偏头痛预防。

该回顾性队列研究分析2020年1月20日至2022年5月19日美国18至65岁偏头痛退伍军人电子健康记录,比较启动与未启动CGRP单抗者的SARS-CoV-2感染及30天住院、需补氧、机械通气或死亡风险。随访28个月,启动者1247例(12.5%)与非启动者780575例(9.6%)SARS-CoV-2检测阳性;删失偏离治疗者后发病率分别为7.4例/1000人月与6.9例/1000人月。ITT与符合方案加权HR分别为0.95(95%CI 0.89-1.01)和0.93(95%CI 0.86-1.02),重症结局OR均无显著差异。作者认为CGRP单抗疫情期间可用于偏头痛预防,但重症事件少,需更大样本重复分析。

要点

  • 启动CGRP单抗者SARS-CoV-2阳性率12.5%(1247例),未启动者9.6%(780575例),随访28个月。
  • 删失偏离治疗者后,启动者发病率7.4例/1000人月,未启动者6.9例/1000人月。
  • ITT加权HR 0.95(95%CI 0.89-1.01),符合方案加权HR 0.93(95%CI 0.86-1.02),均未达统计学显著。
  • 阳性者中,住院OR 0.93(95%CI 0.62-1.41)、需补氧OR 0.77(95%CI 0.45-1.30)、机械通气OR 0.85(95%CI 0.26-2.84)、死亡OR 0.67(95%CI 0.09-5.23),均无显著差异。
  • 作者认为CGRP单抗可在COVID-19疫情期间用于偏头痛预防;因补氧、机械通气、死亡事件少,需更大样本重复分析。

适用人群与场景

  • 美国18至65岁、诊断为偏头痛、2020年1月20日至2022年5月19日期间有COVID-19风险的退伍军人。

研究设计与关键结果

  • 回顾性队列研究,纳入8178652人-试验(354294名退伍军人);启动CGRP单抗9992例(平均[SD]年龄46.0[9.5]岁,53.9%男性),未启动8168660例(平均[SD]年龄46.6[10.2]岁,65.7%男性)。
  • 28个月随访期间,启动者1247例(12.5%)、非启动者780575例(9.6%)SARS-CoV-2检测阳性;删失偏离治疗者后发病率分别为7.4例/1000人月与6.9例/1000人月。
  • ITT与符合方案的反概率加权观察性HR分别为0.95(95%CI 0.89-1.01)和0.93(95%CI 0.86-1.02)。
  • SARS-CoV-2阳性者中,启动与未启动CGRP单抗的30天住院OR 0.93(95%CI 0.62-1.41)、需补氧OR 0.77(95%CI 0.45-1.30)、机械通气OR 0.85(95%CI 0.26-2.84)、死亡OR 0.67(95%CI 0.09-5.23),均无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:需补氧、机械通气、死亡事件少,需在更大样本、疾病后期重复分析。

对床旁实践的改变

  • 作者认为,CGRP单抗可在COVID-19疫情期间用于偏头痛预防。
  • 启动CGRP单抗与SARS-CoV-2检测阳性及重症COVID-19结局无显著关联,支持在偏头痛患者中继续该治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology, is also a key neuroimmune modulator. CGRP antagonists may help mitigate the hyperinflammatory response observed in patients with COVID-19; however, findings from the literature are contradictory, and to date, no study has investigated the safety and effectiveness of CGRP antagonists against COVID-19.

OBJECTIVE: To evaluate the association between CGRP monoclonal antibody (mAb) treatment and risk of SARS-CoV-2 infection and sequela hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed the electronic health records of US veterans aged 18 to 65 years who were diagnosed with migraine disorder and were at risk of COVID-19 between January 20, 2020, and May 19, 2022.

EXPOSURE: Initiation of CGRP mAbs.

MAIN OUTCOMES AND MEASURES: The main outcome was cumulative incidence of SARS-CoV-2 infection. Odds of 30-day hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death were secondary outcomes.

RESULTS: Among 8 178 652 eligible person-trials (354 294 veterans), 9992 (mean [SD] age, 46.0 [9.5] years; 53.9% male) initiated CGRP mAbs and 8 168 660 (mean [SD] age, 46.6 [10.2] years; 65.7% male) did not initiate CGRP mAbs. Over a 28-month follow-up period, 1247 initiators (12.5%) and 780 575 noninitiators (9.6%) tested positive for SARS-CoV-2. After censoring persons who deviated from treatment, the incidence was 7.4 cases per 1000 person-months among initiators and 6.9 per 1000 person-months among noninitiators. The inverse probability-weighted observational analogs of intention-to-treat and per-protocol hazard ratios were 0.95 (95% CI, 0.89-1.01) and 0.93 (95% CI, 0.86-1.02), respectively. No significant differences in the likelihood of hospitalization (odds ratio [OR], 0.93; 95% CI, 0.62-1.41), requiring supplemental oxygen (OR, 0.77; 95% CI, 0.45-1.30), use of mechanical ventilation (OR, 0.85; 95% CI, 0.26-2.84), or death (OR, 0.67; 95% CI, 0.09-5.23) were observed between CGRP mAb initiators and noninitiators who tested positive for SARS-CoV-2.

CONCLUSIONS AND RELEVANCE: In this cohort study, CGRP mAb treatment was not associated with positive SARS-CoV-2 test results or risk of severe COVID-19 outcomes, suggesting that CGRP mAbs may be used for migraine prevention during the COVID-19 pandemic. Given the few events of requiring supplemental oxygen, use of mechanical ventilation, and death, replication analysis in a larger sample of patients later in the course of disease is warranted.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Wang K, Fenton BT, Deng Y, et al. Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Netw Open. 2023. PMID: 37523183. doi:10.1001/jamanetworkopen.2023.26371

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。